A carregar...
Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients
Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was shown to be active in colorectal cancer. Although some patients who harbor K-ras wild-type tumors benefit from cetuximab treatment, 40 to 60% of patients with wild-type K-ras tumors do not respond to cetuximab. Cur...
Na minha lista:
| Publicado no: | Hum Genome Var |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4785572/ https://ncbi.nlm.nih.gov/pubmed/27081524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/hgv.2015.9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|